Study of the Pathophysiological Mechanisms Involved in Bleeding Events (LOWE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01314560|
Recruitment Status : Completed
First Posted : March 14, 2011
Last Update Posted : September 19, 2011
Lowe syndrome is associated with mutations in the OCRL1 gene, which encodes OCRL1, a phosphatidylinositol-4, 5-bisphosphate (PtdIns(4, 5)P (2))5-phosphatase. PtdIns(4, 5)P2, a substrate of OCRL1, is an important signaling molecule within the cell. An abnormal rate of hemorrhagic events was found in a retrospective clinical survey, suggesting platelet dysfunction.
The main objective of the study is to confirm the presence of platelet dysfunction in Lowe syndrome and to characterize this abnormality.
|Condition or disease||Intervention/treatment||Phase|
|Oculocerebrorenal Syndrome||Other: Blood sample||Not Applicable|
Introduction: Lowe syndrome (LS), also known as oculocerebrorenal syndrome of Lowe (OCRL), is a rare X-linked condition characterized by congenital cataracts, defective renal tubule cell function, muscular hypotonia and variable degrees of mental retardation. Patients with LS require frequent surgery, some of which are associated with a severe haemorrhagic risk, such as scoliosis reduction, hip surgery, or eye surgery. In a recent retrospective clinical survey of French LS patients, we observed an abnormal rate of haemorrhagic events, some of which had dramatic outcomes. LS is caused BYMUTATIONS in the OCRL gene, which encodes OCRL, an inositol polyphosphate 5-phosphatase. The preferred OCRLsubstrate is the membrane phospholipid phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2). OCRL also contains a Rho GTPase-activating protein(GAP)-like domain that participates in the regulation of Rho proteins (Rho, Rac, Cdc42), as GTPase-activating proteins or by mediating in protein-protein interactions. PtdIns(4,5)P2 and Rho-dependent signalling play a central role in many important cellular processes, including vesicular trafficking and cytoskeletal organization both of which are very important for platelet function. Thus, modulation of PtdIns(4,5)P2 levels and/or Rho-dependent signalling would be expected to impact platelet function.
Based on the clinical observation, we tested whether hemorrhagic symptom of 6 Lowe patients could be related to homeostasis abnormalities and we found that all the six patients had a prolonged closure time tested by PFA100 analyzer (Platelet Function Analyzer). These results were measured in absence of interfering factor such anemia, thrombopenia, or von Willebrand factor deficiency, thus suggesting platelet dysfunction.
The comprehension of the physiopathology implicated in the abnormal hemorrhagic risk is of major interest in term of prevention and clinical management in Lowe patients who requires frequent surgical care.
The main objective of the study is to confirm the presence of platelet dysfunction in Lowe syndrome and to characterize this abnormality. The secondary aims are to settle a functional test allowing the detection of patients with increasing hemorrhagic risk. Moreover, we could determinate whether platelet is an interesting cellular model, easily available, for further OCRL1 studies in Lowe patients.
We will investigate platelet activation response in 15 Lowe cases and 15 normal cases. The evaluation criteria will include the PFA100, THROMBOELASTOMETRY (ROTEM), aggregation, secretion, adhesion in a flux system and clot retraction. We will also compare molecular (phospho-proteins, phospholipid...) and structural modifications of the non activated platelet and of activating platelet.
The characterization of a platelet activation abnormality in Lowe patients could lead to major benefit for the patients with systematic homeostasis screening and special precautions rules before surgery, often required in this multisystemic condition. Moreover, this study could contribute to go further into PI(4,5)P2 signaling pathways and may provide clues to the interrelationship between these processes in normal metabolism and diseases states.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of the Pathophysiological Mechanisms Involved in Bleeding Events Observed in Patients With Lowe Syndrome|
|Study Start Date :||February 2009|
|Actual Primary Completion Date :||July 2010|
|Actual Study Completion Date :||December 2010|
Other: Blood sample
- The platelet function will be evaluated by comparing the intensity of platelet responses obtained in patient and controls [ Time Frame: 18 months ]
The platelet function will be evaluated by comparing the intensity of platelet responses obtained in patient and controls. Various platelet responses will be studied:
- The measurement of platelet closure time by PFA100
- Aggregation, retraction, secretion and adhesion
- Characterization of abnormalities in platelet-signalling pathways [ Time Frame: 18 months ]Characterization of abnormalities in platelet-signalling pathways
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01314560
|Necker Enfants Malades Hospital, Genetic|
|Paris, France, 75015|
|Principal Investigator:||Geneviève Baujat, MD, PhD||Hôpital Necker Enfants Malades, Paris|